Experimental studies on atherosclerosis-susceptible animals have shown that either genetic deletion, or pharmacological inhibition of IL-1 signals, reduces both the formation and rate of progression of atherosclerotic plaques. This evidence concerns the gene IL1B and atherosclerosis.